Talecris’ Gamunex Gets Leg Up In CIDP
This article was originally published in The Pink Sheet Daily
Executive Summary
Immune globulin’s broader label sure to please merger-bound CSL.
You may also be interested in...
Aussie Biotech CSL Sees Talecris Acquisition As Ticket To Grow Plasma Therapeutics
North Carolina biotech operates 56 plasma collection centers and two manufacturing facilities in U.S.
Talecris Immunoglobulin Therapy Gains Priority Review For CIDP
Supplemental BLA for chronic inflammatory demyelinating polyneuropathy has Sept. 13 user fee date.
Another Hybrid License Deal: Chiesi Buys Majority Stake In Cornerstone
In a creative deal that echoes the strategic tie-up last year between Infinity and Mundipharma, Italian giant Chiesi Farmaceutici is buying a majority stake in Cornerstone Therapeutics, which gets $15.5 million along with U.S. rights for 10 years to Chiesi's marketed lung surfactant Curosurf